PTC Therapeutics, Inc. Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent
PTC Therapeutics, Inc. (PTCT) reported Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent of $0 for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent · last filed 2022-08-04
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2022-06-30 was $0.00.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2022-03-31 was $0.00.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2021-12-31 was $0.00.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2021-09-30 was $0.00.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2021 was $0.00.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2019 was $165.00K, a 8150.00% increase from fiscal 2018.
- PTC Therapeutics, Inc. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2018 was $2.00K.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-08-04 | $0.00 derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | $0.00 derived: sum of 2 quarters · filed 2022-05-03 | $0.00 derived: sum of 3 quarters · filed 2022-05-03 | $0.00 derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $0.00 derived: sum of 2 quarters · filed 2022-02-22 | $0.00 derived: sum of 3 quarters · filed 2022-08-04 | $0.00 10-K · filed 2022-02-22 |
| 2021-09-30 | $0.00 10-Q · filed 2021-10-28 | $0.00 derived: sum of 2 quarters · filed 2022-08-04 | $0.00 10-Q · filed 2021-10-28 | $0.00 derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-08-04 | $0.00 derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-03 | $0.00 derived: sum of 2 quarters · filed 2022-05-03 | $0.00 derived: sum of 3 quarters · filed 2022-05-03 | $0.00 derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $0.00 derived: sum of 2 quarters · filed 2022-02-22 | $0.00 derived: sum of 3 quarters · filed 2022-02-22 | $0.00 10-K · filed 2022-02-22 |
| 2020-09-30 | $0.00 10-Q · filed 2021-10-28 | $0.00 derived: sum of 2 quarters · filed 2021-10-28 | $0.00 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $165.00K 10-K · filed 2022-02-22 | |||
| 2018-12-31 | $2.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |